Shareholder Class Action for King Pharmaceuticals

We served as lead counsel for King Pharmaceuticals, Inc. and its board of directors in shareholder class actions relating to the $3.6 billion buyout of King by Pfizer, Inc.

King Pharmaceuticals (NYSE: KG) is a wholly owned subsidiary of Pfizer based in Bristol, Tennessee. Before being acquired by Pfizer, it was the world’s 39th largest pharmaceutical company.

You Also May Be Interested In:

  • We represented Pharos Capital’s post-acute care provider platform, Charter Health Care Group, in its acquisition of two hospice service providers,...
    Client Type: Private Company
  • Representation of axialHealthcare, a care optimization platform navigating substance use issues for patients, providers, and health plans, in a $15 million Series C round of financing to accelerate its expansion into the substance use disorder (SUD) treatment, and recovery sector. Previous institutional investors Oak HC/FT, .406 Ventures, BlueCross BlueShield Venture Partners (BCBSVP), and Sandbox Advantage Fund led the round.

    We represented axialHealthcare, a care optimization platform navigating substance use issues for patients, providers, and health plans, in a $15...
    Client Type: Private Company
  • Representation of Health Velocity Capital as lead investor in a $30 million Series C funding round for HealthJoy, a healthcare consumer benefits platform. In addition to Health Velocity Capital, other participating investors included U.S. Venture Partners, Chicago Ventures, and Epic Ventures

    We advised Health Velocity Capital as lead investor in a $30 million Series C funding round for HealthJoy, a healthcare...
    Client Type: Private Company